Abstract:UNLABELLED:Our study indicates that recombinant adiponectin induced RANKL and inhibited OPG expression in human osteoblasts through the AdipoR1/p38 MAPK pathway, and these responses contributed to the adiponectin-induced osteoclasts formation in the co-culture of osteoblast and peripheral blood monocytes systems. These findings showed that adiponectin increased osteoclast formation indirectly through stimulating RANKL and inhibiting OPG production in osteoblasts. It also suggests the pharmacological nature of recombinant adiponectin that indirectly induces osteoclasts formation. INTRODUCTION:Recently, adiponectin has emerged as an element in the regulation of bone metabolism, but the mechanism remains. This study was undertaken to investigate the action of adiponectin on osteoclastogenesis through revealing RANKL and osteoprotegerin (OPG) expression in osteoblasts and osteoclast formation. MATERIALS AND METHODS:Real-time quantitative PCR and ELISA were used to detect RANKL and OPG mRNA and protein expression in cultured human osteoblasts. The involved signal pathway was studied using mitogen-activated protein kinase (MAPK) inhibitor and adiponectin receptor 1 (AdipoR1) siRNA. The effects of recombinant adiponectin on osteoclasts formation also were examined in the co-culture systems of osteoblast and peripheral blood monocytes (PBMCs) systems or purified CD14 + PBMCs cultures. RESULTS:Our study showed that recombinant adiponectin induced RANKL and inhibited OPG mRNA expression in human osteoblasts in a dose- and time-dependent manner. Adiponectin also increased soluble RANKL and decreased OPG secretion in osteoblasts conditioned media. Suppression of AdipoR1 with siRNA abolished the adiponectin-regulated RANKL and OPG mRNA expression in osteoblasts. Furthermore, pretreatment of osteoblasts with the MAPK inhibitor SB203580 abolished adiponectin-regulated RANKL and OPG mRNA expression. Adiponectin induced osteoclast formation in the co-culture systems of osteoblast and PBMCs systems, and OPG entirely blocked this response. However, adiponectin had no direct effect on the differentiation of osteoclast precursor purified CD14 + PBMCs. CONCLUSIONS:These data indicate that recombinant adiponectin induced RANKL and inhibited OPG expression in human osteoblasts through the AdipoR1/p38 MAPK pathway, and these responses contributed to the adiponectin-induced osteoclast formation in the co-culture of osteoblast and PBMCs systems. These findings showed that adiponectin increased osteoclast formation indirectly through stimulating RANKL and inhibiting OPG production in osteoblasts. It suggests the pharmacological nature of recombinant adiponectin that indirectly induces osteoclasts formation.

RANKL from bone marrow adipose lineage cells promotes osteoclast formation and bone loss

Bone marrow adipogenic lineage precursors are the major regulator of bone resorption in adult mice

RANKL Signaling in Bone Marrow Mesenchymal Stem Cells Negatively Regulates Osteoblastic Bone Formation

RhoA Promotes Osteoclastogenesis and Regulates Bone Remodeling Through Mtor-Nfatc1 Signaling.

Interplay between bone marrow adiposity and bone resorption in RANKL‐mediated modelled osteoporosis

LncRNA AK077216 promotes RANKL‐induced osteoclastogenesis and bone resorption via NFATc1 by inhibition of NIP45

Primary human bone marrow adipocytes support TNF-α-induced osteoclast differentiation and function through RANKL expression

Inhibiting Monoacylglycerol Lipase Suppresses RANKL-Induced Osteoclastogenesis and Alleviates Ovariectomy-Induced Bone Loss

Low-density lipoprotein receptor deficiency reduced bone mass in mice via the c-fos/NFATc1 pathway

RANKL-independent modulation of osteoclastogenesis

Csf1 from marrow adipogenic precursors is required for osteoclast formation and hematopoiesis in bone

RETRACTED: Crosstalk between adipocytes and M2 macrophages compensates for osteopenic phenotype in the <i>Lrp5</i>-deficient mice (Retracted Article)

RANKL Downregulates Cell Surface CXCR6 Expression Through JAK2/STAT3 Signaling Pathway During Osteoclastogenesis

Adipocytes regulate the bone marrow microenvironment in a mouse model of obesity.

Adiponectin Exerts Its Negative Effect on Bone Metabolism Via OPG/RANKL Pathway: an in Vivo Study.

Osteocyte RANKL is required for cortical bone loss with age and is induced by senescence

Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway.

Osteoblast-induced Osteoclast Apoptosis by Fas Ligand/fas Pathway is Required for Maintenance of Bone Mass

Mutations within the TNF-Like Core Domain of RANKL Impair Osteoclast Differentiation and Activation

RANKL-stimulated TNFα production in osteoclast precursor cells promotes osteoclastogenesis by modulating RANK signaling pathways

Lipopolysaccharide inhibits osteoblast formation and receptor activator of nuclear factor-κB ligand degradation via autophagy inhibition